Cash Flow Statement
Growth Metrics

Ani Pharmaceuticals (ANIP) Gross Profit (2016 - 2026)

Ani Pharmaceuticals' Gross Profit history spans 14 years, with the latest figure at $146.8 million for Q4 2025.

  • On a quarterly basis, Gross Profit rose 33.09% to $146.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $542.1 million, a 48.85% increase, with the full-year FY2025 number at $542.1 million, up 48.85% from a year prior.
  • Gross Profit hit $146.8 million in Q4 2025 for Ani Pharmaceuticals, up from $134.4 million in the prior quarter.
  • Over the last five years, Gross Profit for ANIP hit a ceiling of $146.8 million in Q4 2025 and a floor of -$8.8 million in Q1 2021.
  • Historically, Gross Profit has averaged $73.1 million across 5 years, with a median of $76.2 million in 2023.
  • Biggest five-year swings in Gross Profit: plummeted 131.41% in 2021 and later skyrocketed 443.84% in 2022.
  • Tracing ANIP's Gross Profit over 5 years: stood at $27.0 million in 2021, then surged by 114.22% to $57.9 million in 2022, then surged by 35.11% to $78.2 million in 2023, then soared by 40.98% to $110.3 million in 2024, then surged by 33.09% to $146.8 million in 2025.
  • Business Quant data shows Gross Profit for ANIP at $146.8 million in Q4 2025, $134.4 million in Q3 2025, and $136.8 million in Q2 2025.